Mirum Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mirum Pharmaceuticals generated cash of -$70,944,000, which is more than the previous year. Cash used in financing activities reached the amount of $336,600,000 last year. Net change in cash is therefore $158,323,000.
Cash Flow
| 2019 | -39.36M | -127.78M | 127.17M |
|---|---|---|---|
| 2020 | -89.07M | 37.87M | 181.28M |
| 2021 | -132.75M | 48.54M | 73.46M |
| 2022 | -120.13M | 7.7M | 109.08M |
| 2023 | -70.94M | -107.2M | 336.6M |
MIRM Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 128.00M | 131.34M | 142.08M | 11.97M | 51.96M |
Operating activities | |||||
Net income | -163.41M | -135.66M | -83.98M | -103.27M | -52.55M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 10.82M | 3.68M | 975K | 623K | 324K |
Stock-based compensation expense | 35.02M | 27.00M | 23.08M | 12.55M | 6.07M |
| Deferred income tax benefit | 35.02M | 27.00M | 23.08M | 12.55M | 6.07M |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | -43.97M | -20.72M | 0 | 0 | 0 |
Inventories | -4.39M | -3.44M | -495K | 0 | 0 |
Accounts payable | 30.77M | 7.63M | 22.65M | 3.68M | 10.05M |
Cash generated by operating activities | -70.94M | -120.13M | -132.75M | -89.07M | -39.36M |
Investing activities | |||||
Purchases Of Investments | -27.32M | -132.32M | -198.02M | -74.56M | -152M |
Investments In Property Plant And Equipment | -109K | -278K | -19.02M | -225K | -281K |
Acquisitions Net | -212.76M | -7.97M | -19M | -38.09M | 127.5M |
Cash generated by investing activities | -107.2M | 7.7M | 48.54M | 37.87M | -127.78M |
Financing activities | |||||
Common Stock Issued | 216.68M | 107.36M | 9.01M | 131.87M | 67.2M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 109.72M | 0 | -64.45M | -49.57M | 0 |
Cash used in financing activities | 336.6M | 109.08M | 73.46M | 181.28M | 127.17M |
Net Change In Cash | 158.32M | -3.33M | -10.74M | 130.11M | -39.99M |
Cash at end of period | 286.32M | 128.00M | 131.34M | 142.08M | 11.97M |
| Data source | Data source | Data source | Data source | Data source |